RareKids-CAN Offer Subsidized Services for Investigator-initiated Academic Clinical Trials
RareKids-CAN offers a range of subsidized services for investigator-initiated (academic-led) pediatric rare disease clinical trials. The goal of these services is to stretch project funds further, ensuring greater impact and cost savings. Below is the list of subsidized services offered:
100% Subsidized Services (RareKids-CAN will cover 100% of the cost of the following services):
-
- Consultations: We will conduct a robust consultation to identify areas of needs for your project with valuable involvement from relevant sub platforms based on your project needs to ensure your project receives adequate support.
- High-level project management: An experienced project manager will ensure efficient coordination, oversight, and successful execution from inception to completion for your clinical trial.
- Database build (not including management): We will provide project-specific electronic case report form (e-CRF) development and database management in a validated REDCap database housed at the Women and Children’s Health Research Institute (WCHRI).
- Data Safety Monitoring Board: From our repository of individuals with specific expertise relevant to your project, we facilitate a centralized data safety monitoring board to ensure participant safety and provide expertise on clinical trial conduct for continuation, modification, or termination.
50% Subsidized Services (RareKids-CAN will cover 50% of the total cost of the following services):
-
- Regulatory submissions: We assist study teams in the preparation and submission of clinical trial applications, investigational testing authorizations, and single-patient study applications for regulated clinical trials to Health Canada. We will also assist in adverse event reporting.
- Monitoring: We have a dedicated and experienced monitoring team to perform risk-based remote and on-site monitoring to meet the Health Canada required sponsor obligations.
All other services are 100% cost recovered (i.e., RareKids-CAN will not subsidize)
If you have a clinical trial that require these services or would like to further discuss, you can complete the project intake form.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.